A previously reported prospective study on pancreatic cancer showed that the incidence of grade 3–4 hematological adverse events was higher in patients who were heterozygous for UGT1A1 *6 or UGT1A1 *28 than in patients with wild-type UGT1A1, although the difference did not reach statistical significance. Here, UGT1A1 is linked to familial pancreatic carcinoma.